Captopril in primary pulmonary hypertension

Seven women with primary pulmonary hypertension underwent hemodynamic evaluation, at rest and during exercise, before and after the oral administration of captopril. Dose-response curves were generated for the 25-, 50- and 100-mg doses. Captopril significantly reduced systemic blood pressure and sys...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Circulation (New York, N.Y.) N.Y.), 1983-01, Vol.67 (1), p.155-161
Hauptverfasser: Leier, C V, Bambach, D, Nelson, S, Hermiller, J B, Huss, P, Magorien, R D, Unverferth, D V
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 161
container_issue 1
container_start_page 155
container_title Circulation (New York, N.Y.)
container_volume 67
creator Leier, C V
Bambach, D
Nelson, S
Hermiller, J B
Huss, P
Magorien, R D
Unverferth, D V
description Seven women with primary pulmonary hypertension underwent hemodynamic evaluation, at rest and during exercise, before and after the oral administration of captopril. Dose-response curves were generated for the 25-, 50- and 100-mg doses. Captopril significantly reduced systemic blood pressure and systemic vascular resistance; these effects persisted at submaximal levels of exercise. Captopril did not alter pulmonary artery pressure or resistance, cardiac output or stroke volume at rest or during exercise. Exercise tolerance did not improve. Four of the patients also received captopril chronically for 12 weeks at doses of 75 and 100 mg every 8 hours. Resting and exercise hemodynamic evaluation was repeated at the end of the 12-week period. Except for a persistent reduction in mean systemic blood pressure at rest, chronic captopril administration did not elicit hemodynamic changes. Measured exercise duration did not change during continuous captopril treatment, although one patient reported mild subjective improvement in activity tolerance. In primary pulmonary hypertension, captopril exerts its major effect on systemic vasculature, with little or no effect on the pulmonary circuit. While an occasional patient may experience some clinical improvement with captopril therapy, the majority of adult patients with severe primary pulmonary hypertension will not benefit from its chronic administration.
doi_str_mv 10.1161/01.cir.67.1.155
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_80347119</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>80347119</sourcerecordid><originalsourceid>FETCH-LOGICAL-c485t-ec8d5c0d23ff9240002fb312daa511e06fc1ced0b056739debd67ad2894327ab3</originalsourceid><addsrcrecordid>eNo9kM1LxDAQxYMoa109exL25EXanUmapD1KWXVhQRA9hzRJsdIvk_aw_71dtnh6M_CbN7xHyD1CgihwC5iY2idCJpgg5xckQk7TOOUsvyQRAOSxZJRek5sQfuZVMMlXZCUYEwJ4RJ4KPYz94OtmU3ebWVvtj5thatq-O03fx8H50XWh7rtbclXpJri7Rdfk62X3WbzFh_fXffF8iE2a8TF2JrPcgKWsqnKazk9pVTKkVmuO6EBUBo2zUAIXkuXWlVZIbWmWp4xKXbI1eTz7Dr7_nVwYVVsH45pGd66fgsqApRIxn8HtGTS-D8G7Si0BFII61aMAVbH_UEIqVHM988XDYj2VrbP__NIH-wM7xWCE</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>80347119</pqid></control><display><type>article</type><title>Captopril in primary pulmonary hypertension</title><source>Electronic Journals Library</source><source>MEDLINE</source><source>American Heart Association</source><source>Journals@Ovid Complete</source><creator>Leier, C V ; Bambach, D ; Nelson, S ; Hermiller, J B ; Huss, P ; Magorien, R D ; Unverferth, D V</creator><creatorcontrib>Leier, C V ; Bambach, D ; Nelson, S ; Hermiller, J B ; Huss, P ; Magorien, R D ; Unverferth, D V</creatorcontrib><description>Seven women with primary pulmonary hypertension underwent hemodynamic evaluation, at rest and during exercise, before and after the oral administration of captopril. Dose-response curves were generated for the 25-, 50- and 100-mg doses. Captopril significantly reduced systemic blood pressure and systemic vascular resistance; these effects persisted at submaximal levels of exercise. Captopril did not alter pulmonary artery pressure or resistance, cardiac output or stroke volume at rest or during exercise. Exercise tolerance did not improve. Four of the patients also received captopril chronically for 12 weeks at doses of 75 and 100 mg every 8 hours. Resting and exercise hemodynamic evaluation was repeated at the end of the 12-week period. Except for a persistent reduction in mean systemic blood pressure at rest, chronic captopril administration did not elicit hemodynamic changes. Measured exercise duration did not change during continuous captopril treatment, although one patient reported mild subjective improvement in activity tolerance. In primary pulmonary hypertension, captopril exerts its major effect on systemic vasculature, with little or no effect on the pulmonary circuit. While an occasional patient may experience some clinical improvement with captopril therapy, the majority of adult patients with severe primary pulmonary hypertension will not benefit from its chronic administration.</description><identifier>ISSN: 0009-7322</identifier><identifier>EISSN: 1524-4539</identifier><identifier>DOI: 10.1161/01.cir.67.1.155</identifier><identifier>PMID: 6336605</identifier><language>eng</language><publisher>United States</publisher><subject>Adult ; Blood Pressure - drug effects ; Captopril - therapeutic use ; Cardiac Output - drug effects ; Dose-Response Relationship, Drug ; Female ; Humans ; Hypertension, Pulmonary - drug therapy ; Middle Aged ; Physical Exertion ; Proline - analogs &amp; derivatives ; Pulmonary Wedge Pressure - drug effects ; Stroke Volume - drug effects ; Vascular Resistance - drug effects</subject><ispartof>Circulation (New York, N.Y.), 1983-01, Vol.67 (1), p.155-161</ispartof><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c485t-ec8d5c0d23ff9240002fb312daa511e06fc1ced0b056739debd67ad2894327ab3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,3687,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/6336605$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Leier, C V</creatorcontrib><creatorcontrib>Bambach, D</creatorcontrib><creatorcontrib>Nelson, S</creatorcontrib><creatorcontrib>Hermiller, J B</creatorcontrib><creatorcontrib>Huss, P</creatorcontrib><creatorcontrib>Magorien, R D</creatorcontrib><creatorcontrib>Unverferth, D V</creatorcontrib><title>Captopril in primary pulmonary hypertension</title><title>Circulation (New York, N.Y.)</title><addtitle>Circulation</addtitle><description>Seven women with primary pulmonary hypertension underwent hemodynamic evaluation, at rest and during exercise, before and after the oral administration of captopril. Dose-response curves were generated for the 25-, 50- and 100-mg doses. Captopril significantly reduced systemic blood pressure and systemic vascular resistance; these effects persisted at submaximal levels of exercise. Captopril did not alter pulmonary artery pressure or resistance, cardiac output or stroke volume at rest or during exercise. Exercise tolerance did not improve. Four of the patients also received captopril chronically for 12 weeks at doses of 75 and 100 mg every 8 hours. Resting and exercise hemodynamic evaluation was repeated at the end of the 12-week period. Except for a persistent reduction in mean systemic blood pressure at rest, chronic captopril administration did not elicit hemodynamic changes. Measured exercise duration did not change during continuous captopril treatment, although one patient reported mild subjective improvement in activity tolerance. In primary pulmonary hypertension, captopril exerts its major effect on systemic vasculature, with little or no effect on the pulmonary circuit. While an occasional patient may experience some clinical improvement with captopril therapy, the majority of adult patients with severe primary pulmonary hypertension will not benefit from its chronic administration.</description><subject>Adult</subject><subject>Blood Pressure - drug effects</subject><subject>Captopril - therapeutic use</subject><subject>Cardiac Output - drug effects</subject><subject>Dose-Response Relationship, Drug</subject><subject>Female</subject><subject>Humans</subject><subject>Hypertension, Pulmonary - drug therapy</subject><subject>Middle Aged</subject><subject>Physical Exertion</subject><subject>Proline - analogs &amp; derivatives</subject><subject>Pulmonary Wedge Pressure - drug effects</subject><subject>Stroke Volume - drug effects</subject><subject>Vascular Resistance - drug effects</subject><issn>0009-7322</issn><issn>1524-4539</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1983</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo9kM1LxDAQxYMoa109exL25EXanUmapD1KWXVhQRA9hzRJsdIvk_aw_71dtnh6M_CbN7xHyD1CgihwC5iY2idCJpgg5xckQk7TOOUsvyQRAOSxZJRek5sQfuZVMMlXZCUYEwJ4RJ4KPYz94OtmU3ebWVvtj5thatq-O03fx8H50XWh7rtbclXpJri7Rdfk62X3WbzFh_fXffF8iE2a8TF2JrPcgKWsqnKazk9pVTKkVmuO6EBUBo2zUAIXkuXWlVZIbWmWp4xKXbI1eTz7Dr7_nVwYVVsH45pGd66fgsqApRIxn8HtGTS-D8G7Si0BFII61aMAVbH_UEIqVHM988XDYj2VrbP__NIH-wM7xWCE</recordid><startdate>198301</startdate><enddate>198301</enddate><creator>Leier, C V</creator><creator>Bambach, D</creator><creator>Nelson, S</creator><creator>Hermiller, J B</creator><creator>Huss, P</creator><creator>Magorien, R D</creator><creator>Unverferth, D V</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>198301</creationdate><title>Captopril in primary pulmonary hypertension</title><author>Leier, C V ; Bambach, D ; Nelson, S ; Hermiller, J B ; Huss, P ; Magorien, R D ; Unverferth, D V</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c485t-ec8d5c0d23ff9240002fb312daa511e06fc1ced0b056739debd67ad2894327ab3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1983</creationdate><topic>Adult</topic><topic>Blood Pressure - drug effects</topic><topic>Captopril - therapeutic use</topic><topic>Cardiac Output - drug effects</topic><topic>Dose-Response Relationship, Drug</topic><topic>Female</topic><topic>Humans</topic><topic>Hypertension, Pulmonary - drug therapy</topic><topic>Middle Aged</topic><topic>Physical Exertion</topic><topic>Proline - analogs &amp; derivatives</topic><topic>Pulmonary Wedge Pressure - drug effects</topic><topic>Stroke Volume - drug effects</topic><topic>Vascular Resistance - drug effects</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Leier, C V</creatorcontrib><creatorcontrib>Bambach, D</creatorcontrib><creatorcontrib>Nelson, S</creatorcontrib><creatorcontrib>Hermiller, J B</creatorcontrib><creatorcontrib>Huss, P</creatorcontrib><creatorcontrib>Magorien, R D</creatorcontrib><creatorcontrib>Unverferth, D V</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Circulation (New York, N.Y.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Leier, C V</au><au>Bambach, D</au><au>Nelson, S</au><au>Hermiller, J B</au><au>Huss, P</au><au>Magorien, R D</au><au>Unverferth, D V</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Captopril in primary pulmonary hypertension</atitle><jtitle>Circulation (New York, N.Y.)</jtitle><addtitle>Circulation</addtitle><date>1983-01</date><risdate>1983</risdate><volume>67</volume><issue>1</issue><spage>155</spage><epage>161</epage><pages>155-161</pages><issn>0009-7322</issn><eissn>1524-4539</eissn><abstract>Seven women with primary pulmonary hypertension underwent hemodynamic evaluation, at rest and during exercise, before and after the oral administration of captopril. Dose-response curves were generated for the 25-, 50- and 100-mg doses. Captopril significantly reduced systemic blood pressure and systemic vascular resistance; these effects persisted at submaximal levels of exercise. Captopril did not alter pulmonary artery pressure or resistance, cardiac output or stroke volume at rest or during exercise. Exercise tolerance did not improve. Four of the patients also received captopril chronically for 12 weeks at doses of 75 and 100 mg every 8 hours. Resting and exercise hemodynamic evaluation was repeated at the end of the 12-week period. Except for a persistent reduction in mean systemic blood pressure at rest, chronic captopril administration did not elicit hemodynamic changes. Measured exercise duration did not change during continuous captopril treatment, although one patient reported mild subjective improvement in activity tolerance. In primary pulmonary hypertension, captopril exerts its major effect on systemic vasculature, with little or no effect on the pulmonary circuit. While an occasional patient may experience some clinical improvement with captopril therapy, the majority of adult patients with severe primary pulmonary hypertension will not benefit from its chronic administration.</abstract><cop>United States</cop><pmid>6336605</pmid><doi>10.1161/01.cir.67.1.155</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0009-7322
ispartof Circulation (New York, N.Y.), 1983-01, Vol.67 (1), p.155-161
issn 0009-7322
1524-4539
language eng
recordid cdi_proquest_miscellaneous_80347119
source Electronic Journals Library; MEDLINE; American Heart Association; Journals@Ovid Complete
subjects Adult
Blood Pressure - drug effects
Captopril - therapeutic use
Cardiac Output - drug effects
Dose-Response Relationship, Drug
Female
Humans
Hypertension, Pulmonary - drug therapy
Middle Aged
Physical Exertion
Proline - analogs & derivatives
Pulmonary Wedge Pressure - drug effects
Stroke Volume - drug effects
Vascular Resistance - drug effects
title Captopril in primary pulmonary hypertension
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T07%3A59%3A38IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Captopril%20in%20primary%20pulmonary%20hypertension&rft.jtitle=Circulation%20(New%20York,%20N.Y.)&rft.au=Leier,%20C%20V&rft.date=1983-01&rft.volume=67&rft.issue=1&rft.spage=155&rft.epage=161&rft.pages=155-161&rft.issn=0009-7322&rft.eissn=1524-4539&rft_id=info:doi/10.1161/01.cir.67.1.155&rft_dat=%3Cproquest_cross%3E80347119%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=80347119&rft_id=info:pmid/6336605&rfr_iscdi=true